Straits Times Index
3,236.08 +10.63 (+0.33%) S&P 500
3,963.51 +29.59 (+0.75%) Dow
33,781.48 +183.56 (+0.55%) Nasdaq
11,082.00 +123.45 (+1.13%) BTC-USD
17,223.14 +357.79 (+2.12%) CMC Crypto 200
405.01 +10.32 (+2.62%)
Nuvation Bio Inc. (NUVB)
After hours:
| Previous close | 1.9900 |
| Open | 1.9800 |
| Bid | 1.9800 x 1400 |
| Ask | 2.0300 x 1000 |
| Day's range | 1.9100 - 2.0300 |
| 52-week range | 1.7400 - 10.2800 |
| Volume | |
| Avg. volume | 640,965 |
| Market cap | 434.602M |
| Beta (5Y monthly) | 0.48 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4200 |
| Earnings date | 27 Feb 2023 - 03 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.60 |
- Business Wire
Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
NEW YORK, November 03, 2022--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the third quarter ended September 30, 2022, and provided a business update.
- Business Wire
Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
NEW YORK, August 04, 2022--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the second quarter ended June 30, 2022, and provided a business update.
- Business Wire
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program
NEW YORK, August 01, 2022--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that it will prioritize NUV-868 and development of its novel small molecule DDC platform and discontinue clinical development of NUV-422.
